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blood vessel samples was performed.
RESULTS Hypertensive subjects with VC had higher serum OPN and
OPG levels compared to these without VC, and their expressions
were also increased in the calciﬁc vessels (P <0.05). Interestingly, the
inﬂammatory factors from hypertensive patients with VC were
signiﬁcantly increased in cultured macrophages (P <0.05), and were
regulated by OPN and OPG.
CONCLUSIONS These ﬁndings provided a novel insight that OPN and
OPG-mediated inﬂammatory factors expression in macrophages were
involved in the processes of VC in hypertensive patients.
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OBJECTIVES Multiple unbiased genome-wide wide association studies
have identiﬁedastrong linkbetween9p21.3 locus andatheroscleroticdisease
risk. However, the direct mechanism accounting for the 9p21.3 CAD (Coro-
nary Artery Disease) risk still remains poorly understood and controversial.
Previous work including ours demonstrated that altered expression INK4/
ARF locus by non-coding RNA ANRILmight contribute to the 9p21.3 genetic
atherosclerosis susceptibility. Studies from other groups also suggested
possible physical interaction among 9p21.3, INK4/ARF locus and type I IFN
gene cluster. However, recent study has showed that 9p21 locus does not
affect risk of coronary artery disease through direct induction of type I IFNs.
METHODS To investigate whether type I IFN is co-regulated with
INK4/ARF and contributes to clinical onset of CAD in Han Chinese, we
ﬁrst examined the relationship of IFN subtypes with 9p21.3 variants in
170 healthy individuals in US, followed by plasma IFNa21 measure-
ment in 300 Han Chinese with CAD of different severity.
RESULTS We found that mRNA expression of IFNa21 correlated with
the expression of ARF and cANRIL, as well as rs10757278 CAD risk
allele. The expression of IFNa21 did not correlate with CAD severity
quantiﬁed by coronary angiography but was associated with the age of
CAD onset in Han Chinese.
CONCLUSIONS These data suggest that type I IFNs does not
contribute to CAD severity but may play a role in the age of onset of
CAD, possibly through an ANRIL-mediated co-regulatory mechanism
with INK4/ARF locus.
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OBJECTIVES The aim of this study was to combine clinical criteria
and next-generation sequencing (pyrosequencing) to establish a
diagnosis of familial hypercholesterolemia (FH).
METHODS A total of 39 subjects with a Dutch Lipid Clinic Network
score of 8 (deﬁnite FH clinical diagnosis) were recruited from the
Lipid Clinic at Anzhen Hospital, Beijing, China. Next-generation
sequencing was performed in all subjects using a GenCap Custom
Enrichment Kit (MyGenostics, Beijing, China), a kit that detects in 167
disease genes, relevant with blood lipids and cholic acid metabolism,
including low-density lipoprotein receptor (LDLR), apolipoprotein B
(APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9) 3
known FH-causing genes.
RESULTS A total of 24 mutations were detected in 39 subjects.
Amongst these, 19 mutations were in the LDLR gene, three in the
APOB gene and two in the PCSK9 gene. We also found 151 SNPs and 69
genes relevant with blood lipids. Of these, 40 high frequency SNPs
and top 10 genes were summarized. The fourth, a mutation in LDLR
has not previously been reported; it was found to segregate with high
cholesterol levels in the family of the proband.
CONCLUSIONS Using a combination of clinical criteria and targeted
exome sequencing, we have achieved FH diagnosis with a high success
rate. Furthermore, we identiﬁed a new mutation in the LDLR gene.GW26-e2955
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OBJECTIVES Our previous study showed that decreased GPx-1 ac-
tivity in KD patients was associated with the GPx-1 Pro198Leu poly-
morphism and Se deﬁciency. The purpose of this study is to further
elucidate the association between different Se levels and the
GPx-1P198L.
METHODS GPx-1P198L transgenic mice (Tg) were generated and fed by
control diet (CON, 0.1-0.2mg Se/kg) or Se-deﬁcient diet (SD, <0.02 mg
Se/kg) for 12 weeks. Heart GPX-1 expression was detected by realtime
RT-PCR and western blot. Echocardiographic measurements were
performed to measure the cardiac function. Serum Se was analyzed by
a ﬂameless atomic absorption spectrophotometry method. Myocardial
GPx activity was spectrophotometrically measured using a cellular
glutathione peroxidase activity assay kit. Caspase-9 and 3 levels were
detected by western blot.
RESULTS In GPx-1P198L transgenic mice, heart GPx-1 expression was
remarkable upregulated when compared with wide type (WT) control
(P<0.05), whereas, GPx-1 activity showed no difference (P>0.05). Se
deﬁciency resulted in cardiac systolic dysfunction both in WT and Tg
mice and showed no difference (P>0.05). Se deﬁciency led to
myocardial ﬁbrosis accompanied by increased expression of caspase-9
and -3 In WT mice. But in Tg mice, expression levels of caspase-9 and
-3 were attenuated, whereas, myocardial ﬁbrosis was not signiﬁcantly
decreased.
CONCLUSIONS Overexpression of GPx-1P198L did not show evident
protection against cardiac remodeling and failure. These results
further documented that GPx-1P198L might be a functional poly-
morphism which may cause functional deﬁciency of GPx-1.GW26-e3821
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OBJECTIVES Ischemic postcontioning (IPoC) is an effective method
to prevent myocardial ischemia reperfusion injury (MIRI), but its
cardioprotection is usually blocked in the presence of hypercholes-
terolemia (HC) and the potential mechanism is still unknown.
METHODS In this study, we investigated the roles of reperfusion
injury salvage kinase (RISK) and apoptosis-related pathways in the
attenuation of cardioprotection of IPoC in the presence of HC.
RESULTS The results showed that IPoC signiﬁcantly decreased the
infarct size and apoptosis, improved the recovery of ischemic
myocardium, but these beneﬁcial effects were reversed by high
cholesterol diet-induced HC. Moreover, we also found that HC
inhibited the phosphorylation of Akt and ERK1/2 which usually acti-
vated by IPoC in normal heart, induced excessive apoptosis by down-
regulating Bcl-2 and up-regulating Bax, cytochrome c, caspase 9 and
caspase 3 when compared with that in normal heart.
CONCLUSIONS Taken together, our results demonstrated that the
cardioprotection of IPoC was abolished by HC, which was associated
with inactivation of RISK signal pathway and dysregulation of
downstream apoptosis-related pathway.
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OBJECTIVES Brugada syndrome (BrS) is a clinical entity with high
incidence of sudden cardiac death. Diagnosis of BrS solely relies on
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ﬁnd biomarkers for BrS diagnosis and to investigate possible mecha-
nism of BrS, we conducted this study.
METHODS Twenty-ﬁve control patients, 25 BrS patients without
SCN5A mutations and 20 BrS patients with SCN5A mutations were
included in this study. Blood samples were collected in BD Vacutainer
9NC 0.129M (BD Biosciences). White blood cells were separated using
Lympholyte-H sterile liquid. Total RNA was isolated by using Trizol
(Life Technologies) and Direct-Zol RNA MiniPrep Kit and was
reverse transcribed with QuatntiTect Reverse Transcription Kit (Qia-
gen). Real-time quantitative PCR (Q-PCR) analysis was performed
using 7500-Fast Real-Time PCR Systems with MESP1 speciﬁc primers
and probes and TaqMan Gene Expression Master Mix (Life Tech-
nologies). MESP1 expression level was normalized by GAPDH. Differ-
ences between the groups were examined by one way ANOVA and
t-tests. Results with p <0.05 were considered statistically signiﬁcant
in all analyses.
RESULTS Among 5 cardiac speciﬁc transcription factors tested, MESP1
is one of the two expressed in white blood cells (WBC). WBC levels of
MESP1 were signiﬁcantly lower in BrS patients than that in normal
control group (1.080.8 in control group vs. 0.660.38 in BrS patients
without SCN5A mutation, 0.440.42 in BrS patients with SCN5A
mutation respectively, P ¼0.001 by ANOVA analysis). T-tests revealed
that the difference between control group, BrS group without SCN5A
mutation and BrS group with SCN5A mutation is statistically signiﬁ-
cant (P ¼0.012 and P¼0.000 respectively). Nevertheless, there was no
difference detected between the two BrS groups (P¼0.215). The area
under the Receiver Operating Characteristics analysis (ROC) curve for
prediction of BrS using MESP1 levels is 0.775 (95% CI 0.668, 0.882,
asymptotic Sig.¼0.000). At the optimal cutoff, the corresponding
maximum sensitivity and speciﬁcity were 0.62 (95% CI: 0.47, 0.76)
and 0.88 (0.69, 0.97), respectively.
CONCLUSIONS MESP1 is a major cardiac speciﬁc transcription factor
that expresses in white blood cells. Patients with BrS have reduced
circulating MESP1. Our results suggest that assessment of circulating
MESP1 may be used as a biomarker for BrS diagnosis. Our results also
suggest that decreased expression of MESP1 may be one of patho-
physiological mechanism of BrS.GW26-e5401
The effect of atorvastatin on endogenous H2S formation in red blood cell
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OBJECTIVES To conﬁrm whether can atorvastatin affect the level of
H2S in plasma through the observation on atherosclerosis model of
rabbits, to assess whether atorvastatin can affect the formation of H2S
from erythrocytes. We would like to know more about the mechanism
of the effect of statins on endogenous H2S formation, for providing
new ideas of variant of H2S-directed pharmacotherapy.
METHODS We chose 36 male Japanese big ear rabbits and divide
into 3 groups randomly, including normal group, high-fat-fed
without medicine group(control group) and high-fat-fed with medi-
cine group(statin group). 12 rabbits in the normal group are given
normal diet. Others 24 rabbits are given high fat diet for 12 weeks.
Rabbits in statin group are given atorvastatin 20mg everyday for 8
weeks (13 to 20 weeks). Determinating the level of H2S and MPST
from erythrocytes and the level of H2S in plasma to examine
mechanism of the effect of statins on endogenous H2S formation.
We measure the level of H2S in plasma by sensitive sulphur elec-
trode assay, measure MPST by western blotting. According to the
principle of MPST enzyme catalytic reaction, we measure the level
of H2S from erythrocytes.
RESULTS The level of H2S released from erythrocytes in high-fat-fed
group was signiﬁcant higher than normal group (p <0.05). There were
little differences in the level of H2S in red blood cell among each group
after 8 weeks (p >0.05). The level of H2S released from erythrocytes
in normal group had no changes before and after observation, but it
reduced remarkably in high-fat-fed without medicine group after
observing 8 weeks (p<0.05), it had little changes in high-fat-fed with
medicine group after taking atorvastatin 8 weeks (P >0.05). MPST
expression in erythrocytes were resemblance among each group
(p >0.05). The level of H2S in plasma in high-fat-fed without medicine
group was signiﬁcant lower than normal group (p <0.05). It was
obviously higher in high-fat-fed with medicine group than in high-
fat-fed without medicine group (p <0.05). The level of H2S in plasma
in high-fat-fed with medicine group was lower than normal group,
but no statistical difference (p >0.05).CONCLUSIONS Atorvastatin increase net H2S production by inhibit-
ing its mitochondrial oxidation and reducing CoQ concentration.
However atorvastatin can not affect the formation of endogenous H2S
released from erythrocytes depended mainly on MPST pathway.
Therefore atorvastatin can not affect endogenous H2S formation in red
blood cell.
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OBJECTIVES Glycated albumin (GA) and the endogenous secretory
receptor for advanced glycation endproducts (esRAGE) may modulate
risk related to atherosclerosis. We tested the hypothesis that elevated
GA and reduced esRAGE in serum are associated with adverse clinical
outcomes in patients with type 2 diabetes and stable coronary artery
disease (CAD).
METHODS We determined GA and esRAGE serum levels in 576
consecutive patients with type 2 diabetes and stable CAD undergoing
sirolimus-eluting stent (SES)-PCI. The primary endpoint was the
incidence of major adverse cardio-cerebral events (MACCE) including
cardiac death, non-fatal myocardial infarction, and non-fatal stroke
during a 2-year follow-up. The secondary endpoint was the occur-
rence of clinically driven repeat revascularization during a 2-year
follow-up. The prognostic value of GA and esRAGE was determined
with the Cox-proportional hazards model after adjustment for
covariates.
RESULTS A total 40 patients (6.9%) experienced MACCE, and 108
(18.8%) patients underwent repeat coronary revascularization during
the follow-up. Serum GA levels correlated positively (both p<0.001),
while serum esRAGE levels negatively (both p<0.05), with the pri-
mary and secondary endpoints, respectively. Serum GA (HR¼1.220,
95% CI 1.160-1.283; HR¼1.152, 95% CI 1.113-1.191, respectively; both
p<0.001) and esRAGE (HR¼0.597, 95% CI 0.407-0.874; HR¼0.751, 95%
CI 0.613-0.919, respectively; both p<0.01) levels remained indepen-
dent predictors of the primary and secondary endpoints after
adjustment for possible confounders.
CONCLUSIONS Serum GA and esRAGE are novel predictors of long-
term clinical outcomes in patients with type 2 diabetes and stable
CAD. Increased serum GA and decreased esRAGE are associated with a
poor prognosis in such patients.
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OBJECTIVES Pre-clinical studies have shown that hypoxia pre-
conditioning can enhance stem cell therapeutic potential for
myocardial repair. We sought to investigate the safety and feasibility
of intracoronary administration of hypoxia-preconditioned bone
marrow cells (HP-BMCs) for acute ST segment elevation myocardial
infarction (STEMI).
METHODS We randomized 22 patients with acute STEMI to receive
intracoronary administration of normoxia BMCs (N-BMCs) (n¼11) or
HP-BMCs (n¼11) following successful revascularization. Another
14 patients were recruited as the control (n¼14).
